A computer-implemented method is provided, which determines at a prediction time tp, a likelihood of kidney failure of a patient within an amount of time Δt. The method comprises receiving input data, the input data comprising a recent creatinine level cR or recent eGFR eGFRR, and one or more of the following: (a) an initial creatinine level c0 and either: a time t0 at which the initial creatinine level c0 was measured, or a time interval ΔT0=tp−t0; (b) an initial estimated glomerular filtration rate (eGFR) eGFR0 and either: a time t0 at which the initial eGFR was determined, or a time interval ΔT0=tp−t0; (c) for a plurality of past creatinine level measurements ci measured at a respective times ti, a statistical parameter derived from a linear regression of the plurality of past creatinine level measurements; and (d) for a plurality of past eGFR values eGFRi determined at respective times ti, a statistical parameter derived from a linear regression of the plurality of past eGFR values; and applying a machine-learning model to the input data to generate an output indicating the likelihood of kidney failure within the given amount of time Δt. Corresponding training methods and systems are also provided.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
2.
THERMAL CONTROL DEVICE FOR TEMPERATURE CYCLING, METHOD FOR CONTROLLING TEMPERATURE CYCLING USING A THERMAL CONTROL DEVICE, AND SYSTEM FOR CONTROLLING TEMPERATURE OF A SAMPLE USING A THERMAL CONTROL DEVICE
In one embodiment, a thermal control device (110) adapted for temperature cycling is provided. The thermal control device (110) comprises a thermally conductive heat spreader layer (118) comprising a first side surface and a second side surface. A heater circuit (120) is disposed adjacent to and in thermal contact with at least one of the first side surface and the second side surface of the thermally conductive heat spreader layer (118). At least one thermal interface material layer (114) is disposed adjacent to and in thermal contact with one of the first side surface and the second side surface of the thermally conductive heat spreader layer (118). A cooling block (116) is disposed adjacent to and in thermal contact with the thermal interface material layer (114). The cooling block (116) is adapted to conduct heat energy away from the thermally conductive heat spreader layer (118). A controller is coupled to and adapted to control the heater circuit (120). In another embodiment, a diagnostic test device is provided.
A computer-implemented training method (110) of training at least one trainable model is disclosed for classifying a patient's health condition into a systemic inflammatory state (168, 170, 172) selected from a predetermined group of at least three systemic inflammatory states (168, 170, 172). The method comprises: a. providing the trainable model; b. retrieving labeled training patient data, the training patient data comprising gene expression data of patients having known systemic inflammatory states (168, 170, 172); and c. training the trainable model on the labeled training patient data. Further disclosed is a computer-implemented classification method (112) of classifying a patient's health condition into a systemic inflammatory state (168, 170, 172) selected from a predetermined group of at least three systemic inflammatory states (168, 170, 172) and systems, computer programs and computer-readable storage media for performing the methods.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
The present invention relates to the field of diagnostics. In particular, it relates to a method for assessing systemic inflammation in a subject exhibiting symptoms thereof comprising a) determining in a sample of said subject the amounts of biomarkers from a group of biomarkers selected from i) a first group of biomarkers comprising: POMK, NEK6, KCNA5, LARGE2, ZNF425, NACA2, CFAP57, SPINT1, ZNF492, and S100A6, ii) a second group of biomarkers comprising: NEK6, SRPK3, TNFSF8, S100A6, NMUR1, DHFR, HIST1H4D, ZDHHC4, TRAF3, and SGMSlor iii) a third group of biomarkers comprising: C9orfl35, ZNF425, ACOT4, SPDYA, DAPP1, LY86, ZPBP2, RPL3L, UPK1B, and APBB3, b) comparing said determined amounts of biomarkers from said group of biomarkers to a reference, and c) assessing systemic inflammation in the subject. Further, the present invention, in general, relates to the use of the amounts of said biomarkers in a sample of a subject exhibiting symptoms of systemic inflammation for assessing systemic inflammation. Moreover, contemplated are a device and a kit for assessing systemic inflammation.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
The invention relates to a laboratory device (1) for handling laboratory sample container racks (50), the laboratory device (1) comprising a base (2) extending horizontally, the base (2) being adapted to support laboratory sample container racks (50) placed thereon, a first finger (3) being movable relative to the base (2), the first finger (3) being adapted to position a laboratory sample container rack (50) on the base (2), a second finger (4) being adapted to horizontally counteract the first finger (3) so that the laboratory sample container rack (50) positioned on the base (2) is holdable in between the first finger (3) and the second finger (4), a down-holder (5) being movable relative to the base (2), the down-holder (5) being adapted to releasably vertically secure the laboratory sample container rack (50) positioned on the base (2), and a linkage (6) which motion-couples the first finger (3) and the second finger (4) and the down-holder (5) to one another.
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
A method for characterization of a mass spectrometry instrument (100) comprising at least one mass analyzing cell (102, 104, 106) is proposed. The method comprising the steps of analyzing a sample (110) comprising at least one substance having a known molecular weight by means of the mass spectrometry instrument (100) so as to provide a mass spectrum (116, 118, 144, 146) of the sample (110), determining an outer envelope and an inner envelope of the mass spectrum (116, 118, 144, 146), calculating a squared difference between the outer envelope and the inner envelope, and determining a deviation of the calculated squared difference from a theoretical mass to charge ratio value of the substance.
A method for operating a laboratory system having a plurality of sample containers; a plurality of laboratory devices to handle the sample containers, the sample containers being assigned for handling to the target device; and a control device configured to control assignment of the sample containers to the target devices; and assigning the sample containers. The assigning comprises: determining a target device workload state for each target device, the workload state being between a first range limit and a second range limit, and determined according to a metric being proportional to a resource target device state indicative of sample containers assigned to the target device, and a power of an output flow of the target device, assigning the sample containers to the target devices according to the target device workload states; and providing sample containers to the plurality of target devices. Furthermore, a laboratory system is provided.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G06Q 10/0631 - Resource planning, allocation, distributing or scheduling for enterprises or organisations
G06Q 10/0639 - Performance analysis of employeesPerformance analysis of enterprise or organisation operations
8.
METHOD FOR OPERATING A SORTER DEVICE IN AN IVD LABORATORY SYSTEM AND IVD LABORATORY SYSTEM
The present disclosure refers to a method for operating a sorter device in an IVD laboratory system, the method comprising providing a sorter device in an IVD laboratory system provided with a system operation controller, the sorter device having a plurality of sample container racks each provided with reception holes for receiving sample containers, a handling device configured to pick sample containers from and place sample containers in the reception holes of the sample container racks, a sorter device controller configured to control operation of the sorter device and connectable to the system operation controller, and an output device functionally connected to the sorter device controller and configured to output at least one of audio data and video data. The sorter device is configured in a pre-operation process, the configuring comprising: assigning the plurality of sample container racks to a plurality of processing sub-targets conducted by the IVD laboratory system in operation, wherein a first sample container rack is assigned to a first processing sub-target and a second sample container rack is assigned to a second processing sub-target which is different from the first processing sub-target, and assigning to the first sample container rack a first threshold value indicative of a first threshold number of sample containers in the first sample container rack, wherein the first threshold number of sample containers is smaller than a maximum number of sample containers receivable in the first sample container rack. The sorter device is operated in an operation process, the operating comprising: placing sample containers in the reception holes of the first sample container rack by the handling device, determining a first present number of sample containers received in the first sample container rack by the sorter device controller, comparing the first present number of sample containers to the first threshold value by the sorter device controller, and if the first present number of sample containers is equal to or greater than the first threshold value, outputting a first warning data through the output device. Furthermore, an IVD laboratory system is provided.
There is disclosed a method and sensor for detecting a plurality of analytes in bodily fluid, the sensor comprising electrodes including a first working electrode, a second working electrode, a third working electrode, a counter electrode, and a reference electrode; wherein the first working electrode is configured to detect a first signal indicative of a first analyte concentration using potentiometry; wherein the second working electrode is configured to detect a second signal indicative of a second analyte concentration using amperometry; wherein the third working electrode is configured to detect a third signal indicative of a third analyte concentration using amperometry; wherein the first analyte, the second analyte, and third analyte are different analytes; wherein the first signal, the second signal, and the third signal are detected using the same reference electrode; wherein at least part of the detection of the first signal occurs simultaneously with the detection of the second signal; wherein the second signal and third signal are detected using the same counter electrode; wherein at least part of the detection of the second signal occurs simultaneously with the detection of the third signal; and wherein at least one of the second working electrode and third working electrode is continuously polarized by application of a polarization voltage during detection of the first signal, second signal and third signal.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1468 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means
G01N 27/27 - Association of two or more measuring systems or cells, each measuring a different parameter, where the measurement results may be either used independently, the systems or cells being physically associated, or combined to produce a value for a further parameter
G01N 33/49 - Physical analysis of biological material of liquid biological material blood
G01N 33/70 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving creatine or creatinine
G01N 33/487 - Physical analysis of biological material of liquid biological material
A61B 5/1495 - Calibrating or testing in vivo probes
G01N 33/62 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving urea
G01N 33/64 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving ketones
G01N 33/98 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving alcohol, e.g. ethanol in breath
10.
METHOD FOR PREPARING ACID RESISTANT MAGNETIC PARTICLES AND ACID RESISTANT MAGNETIC PARTICLES
In a first aspect, the invention relates to a method for preparing a magnetic bead comprising at least one magnetic particle (M) and a silica coating, wherein the silica coating comprises at least two silica layers, the method comprising steps (a) to (d), wherein at least one of steps (b), (c) and (d) is/are done under sonication, wherein sonication is done with an amplitude (peak-to-peak) in the range of from 50 to 250 μm. A second aspect of the invention is related to a magnetic bead comprising (i) at least one magnetic particle (M) and (ii) a silica coating, wherein the silica coating comprises at least two silica layers; wherein the magnetic bead is stable against 7.5 M hydrochlorid acid and has a metal (cation) leaching rate in 7.5 M hydrochloric acid in the range of from 0.1 to 10%, wherein the metal (cation) leaching is determined according to a complex formation of Fe2+ with bathophenanthroline according to Reference Example 8.2. In a third aspect, the invention relates to a functionalized magnetic bead comprising at least one, magnetic bead according to the second aspect, wherein an outer silica layer is functionalized with at least one group selected from the group consisting of amino group, azide group, alkyne group, carboxyl group, thiol group, epoxy group, aryl group and alkyl group. A fourth aspect of the invention is directed to a process for functionalizing a magnetic bead according to the second aspect comprising at least one magnetic particle (M) and a silica coating, wherein the silica coating comprises at least two silica layers. A fifth aspect of the invention is related to a method for preparing magnetic Fe3O4 supra particles and a sixth aspect relates to the use of a magnetic bead according to the second aspect or of a functionalized according to the fourth aspect for immobilization of acid stable biocatalysts or for solid-phase organic synthesis using acid-stable linker.
H01F 1/33 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties of inorganic materials characterised by their coercivity of soft-magnetic materials mixtures of metallic and non-metallic particlesMagnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties of inorganic materials characterised by their coercivity of soft-magnetic materials metallic particles having oxide skin
H01F 1/00 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties
H01F 1/34 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties of inorganic materials characterised by their coercivity of soft-magnetic materials non-metallic substances, e.g. ferrites
11.
METHOD OF CONTROLLING THE FUNCTIONALITY OF AN ANALYTICAL SYSTEM
A method of controlling the functionality of an analytical system (110) is disclosed. The method comprises: a. providing at least one container (114) containing at least one control fluid, the container (114) comprising at least one identifier (124), wherein the identifier (124) comprises at least one identification number of the container (114); b. reading the identifier (124) of the container (114) by using at least one reading device (113) of the analytical system (110); and c. performing a database query in a database (116) of the analytical system (110), the database (116) containing database entries (130) for a plurality of known containers (114) comprising identification numbers of the known containers (114) and assigned expiry information for the respective known containers (114), the database query comprising checking if the container (114) already has a database entry (130) in the data- base (116). Further, an analytical system (110) comprising at least one analytical device (112) for determining an analyte concentration in a sample of a bodily fluid is disclosed.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G01N 33/49 - Physical analysis of biological material of liquid biological material blood
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
There is disclosed an electrode for an electrochemical immunoassay; wherein the electrode is functionalized with at least one antibody or fragment thereof configured to bind to at least one analyte; and wherein the at least one antibody or fragment thereof is conjugated with at least one redox species such that the electrochemical activity of the at least one redox species is altered when the at least one antibody or fragment thereof binds to the at least one analyte.
The present invention relates to methods of assessing heart failure (HF), determining the risk of developing HF, monitoring HF, classifying HF, risk stratification and prognosis in patients with HF and determining the therapeutic effect of a treatment regimen for HF in a subject by determining the level of one or more cardiac related (poly)peptide biomarkers in the interstitial fluid (ISF) from the subject, and comparing the determined level to a reference value. Further this invention refers to the use of ISF in the methods described herein.
A method is provided for determining at least one container information (coi) about a laboratory sample container, wherein the method comprises the steps:
a) acquiring an image (ibc) comprising a brightness and/or color information (bci) of a possible region of the container,
b) acquiring a map (md) comprising a depth information (di) of the region, and
c) determining the container information (coi) by fusing the brightness and/or color information (bci) and the depth information (di).
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
G06V 10/80 - Fusion, i.e. combining data from various sources at the sensor level, preprocessing level, feature extraction level or classification level
A position tracking system for tracking a relative position between connected modules. A target is arrangeable on and/or within a first connected module, the connected modules mechanically interacting for transporting objects between modules; a position sensor is arrangeable on and/or within a second connected module and is configured for generating a sensor signal according to a relative position between the position sensor and target, a processing unit configured for tracking a relative position between the connected modules from the sensor signal; and a second sensor is configured for generating a second sensor signal according to at least a second parameter, wherein the second sensor is a temperature sensor and/or a humidity sensor, the processing unit being configured for considering the second sensor signal when determining the relative position between the connected modules. Further disclosed are related monitoring systems and methods for tracking and monitoring at least two connected modules.
A method of handling laboratory sample containers is presented. The method comprises moving a laboratory sample container to a target position. The target position is a position at which the laboratory sample container is inserted into a corresponding orifice of a laboratory sample container rack provided that the laboratory sample container rack is placed at an intended position. The laboratory sample container is prevented from moving horizontally more than a predetermined horizontal distance if inserted into the corresponding orifice of the laboratory sample container rack. The method also comprises applying a force in a horizontal direction (xy) to the laboratory sample container, determining if the laboratory sample container moves in the horizontal direction (xy) more than the predetermined horizontal distance, and performing an error procedure if it is determined that the laboratory sample container moves in the horizontal direction (xy) more than the predetermined horizontal distance.
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
The present invention relates to a novel monoclonal antibody that specifically binds to a conformation dependent epitope on human thymidine kinase 1 (hTK-1; SEQ ID NO:1), to methods for quantifying hTK-1 employing the antibody and to the use of the anti-hTK-1 antibody in quantifying hTK-1
The present invention relates to methods of diagnosing whether a subject has endometriosis, uterine/pelvic pathology and/or endometriosis and/or uterine/pelvic pathology associated neuropathic pain, to methods of determining the therapeutic effect of a treatment regimen for endometriosis, uterine/pelvic pathology and/or endometriosis and/or uterine/pelvic pathology associated neuropathic pain, and methods of monitoring endometriosis, uterine/pelvic pathology and/or endometriosis and/or uterine/pelvic pathology associated neuropathic pain progression in a subject, by determining the amount or concentration of EphA1 in a sample of the subject, and comparing the determined level to a reference value.
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
The present invention relates to monoclonal antibodies binding to the Receptor Binding Domain of the Spike protein of SARS-CoV-2 virus, nucleic acids encoding said antibody, host cells producing the same, compositions and kits comprising said antibodies, method of detecting SARS-CoV-2 virus in a sample comprising using said antibodies and methods of using said antibodies in immunoassays.
A computer-implemented method of differentiating between lymphoid blast cells and myeloid blast cells comprises: receiving a digital image containing one or more blast cells; applying a parametric model classifier to one or more portions of the digital image each containing a respective blast cell, the parametric model configured to generate an output indicative of whether each blast cell is a lymphoid blast cell or a myeloid blast cell. Computer-implemented methods of training a parametric model are also provided, as well as a clinical decision support system relying on the computer-implemented method of classifying blast cells.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
A computer-implemented method is provided that includes transmitting, by a master node to a plurality of computing nodes, definition information about an initial medical validation model (410): performing, by the master node, a federated learning process together with the plurality of computing nodes (420), to jointly train the initial medical validation model using respective processed local training datasets available at the plurality of computing nodes, the respective local training datasets being processed by the plurality of computing nodes based on the definition information; and determining, by the master node, a final medical validation model based on a result of the federated learning process (430). Through the solution, by means of federated learning, it addresses the data security and privacy concerns from local sites owning.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
H04W 84/02 - Hierarchically pre-organised networks, e.g. paging networks, cellular networks, WLAN [Wireless Local Area Network] or WLL [Wireless Local Loop]
22.
MR-PROADM MARKER PANELS FOR EARLY DETECTION OF SEPSIS
The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being MR-proADM, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: sFlt-1, GDF15 and ESM1, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being MR-proADM and a second biomarker selected from the group consisting of: sFlt-1, GDF15 and ESM1, or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
The invention relates to a single-use dispenser (1) for supplying a control liquid (L) to an analytical device, the single-use dispenser (1) comprising a blow-molded vessel (2) fluid-tightly delimiting an interior volume (3), and a volume (4) of the control liquid (L), wherein the volume (4) of the control liquid (L) is stored within the interior volume (3), and wherein the blow-molded vessel (2) has a predetermined breaking point (5) adapted to form an outlet aperture (8) for the control liquid (L) by breaking the blow-molded vessel (2) in its predetermined breaking point (5).
The present invention provides a screening method for obtaining an antibody composition comprising at least two different monoclonal antibodies. The invention also relates to said antibody composition, and its use. Further, the invention provides a kit comprising said antibody composition. The invention also provides a method for determining a level of antibodies directed to an antigen in a sample.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
G01N 33/96 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood or serum control standard
25.
METHODS FOR DETERMINING MS REAGENT PARAMETERS VIA LEACHABLE COMPOUNDS
The present invention relates to a method for determining a mass spectrometry (MS) reagent stored in a storage container for a period of time and/or at least one storage parameter thereof, said method comprising (a) determining at least one leachable compound of said storage container; (b) comparing the at least one leachable compound determined in step (a) to a reference, and (c) determining said MS reagent and/or at least one storage parameter thereof based on the comparing in step (b); The present invention also relates to a method of quality assurance of an MS analysis, to a data carrier, an MS system, and a kit related thereto.
An automatic analyzer 101 includes a judgment part 118f which descends a probe 201 in the direction of a reagent 205 and suspends the downward movement of the probe 201 at a first position PT higher than a liquid level value P0 assumed to be a height of a liquid level by a first predetermined value Db. The judgment part 118f determines that the reagent 205 is in a normal state when the liquid level is not detected by an electrostatic capacity sensor 206 at the first position PT. Further, the judgment part 118f determines that the reagent 205 in an abnormal state when the liquid level is detected by the electrostatic capacity sensor 206 before reaching the first position PT. An automatic analyzer capable of reducing consumption of consumables produced at the time of reagent registration compared with conventional cases is provided.
The present invention relates to antibodies and antigen-binding fragments thereof, in particular (ds)Fv fragments. The invention also relates to methods of producing these antibodies and fragments thereof as well as their uses and corresponding polynucleotides and kits comprising the same.
The present invention is directed to a method for predicting the risk of a female subject to develop postpartum HELLP syndrome, postpartum preeclampsia, or postpartum eclampsia. The method is based on the determination of the levels of i) sFlt-1 and PlGF, or ii) Endoglin and PlGF in a first sample obtained from said subject before delivery of baby, and a second sample of from said subject obtained after delivery of baby. Moreover, encompassed by the invention are devices and kits for carrying out the method of the present invention.
An in-vitro diagnostic (IVD) analyzer 200 comprising an optical detection unit 217 comprising a cuvette 214 for the optical measurement of a biological sample 2, 2′ is herein disclosed. The IVD analyzer 200 further comprises a piezo actuator 218 arranged on one side of the cuvette 214 configured to transmit ultrasonic waves 254, 254′ through the cuvette 214, a piezo receiver 218′ arranged on the opposite side of the cuvette 214 configured to receive ultrasonic waves 255, 255′, 255″ transmitted through the cuvette 214 and a controller 250 configured to operate according to either a lysis operating mode (L) or an air-detection operating mode (AD). According to the lysis operating mode (L) the piezo actuator 218 is configured to transmit ultrasonic waves 254′ through the cuvette 214 for disrupting cellular particles contained in the biological sample 2. According to the air-detection operating mode (AD) the piezo actuator 218 is configured to transmit ultrasonic waves 254 through the cuvette 214 and the controller 250 is configured to correlate changes in amplitude and/or shifts of phase of the ultrasonic waves 255, 255′, 255″ received by the piezo receiver 218′ relative to reference values with an eventual presence and quantity of air 3 in the cuvette 214, in order to determine if the optical measurement of the biological sample 2, 2′ is affected by the presence of air 3. A respective automated method of operating the in-vitro diagnostic analyzer 200 in order to determine if the optical measurement of the biological sample 2, 2′ is affected by the presence of air is herein also disclosed.
A method of cross-flow filtering wastewater from a diagnostic apparatus or a laboratory analyser, wherein the wastewater comprises nanoparticles and/or microparticles, and the wastewater is streaming in a laminar flow across a surface of a filter membrane, the method comprising: (a) streaming the wastewater across the surface of the filter membrane with a flow rate, so that the flow of the wastewater is a laminar flow with a Reynolds number (Re) of smaller than 500; (b) streaming the wastewater in pulse cycles across the surface of the filter membrane, wherein each pulse cycle comprises one active phase in which the wastewater is under a duty pressure and one inactive phase in which the wastewater is under an inactive pressure, wherein the inactive pressure is no more than 10% of the duty pressure and the active phases have a duration of greater than 50% of the corresponding pulse cycles; and (c) separating the nanoparticles and/or microparticles from the wastewater when the wastewater passes through the filter membrane. Also described is a cross-flow filtration system configured for performing the method.
A healthcare data system. The system comprises a data protection entity configured to: sign at least a portion of a routing header of a data packet with a private key held by the data protection entity, the data packet including a payload and a routing header, the payload including healthcare data and the routing header indicating an intended consumer of the data packet; and transmit the data packet on towards the intended consumer. The healthcare data system further comprises one or more data receivers, each configured to: receive the data packet; and verify the signed routing header.
The present invention provides a novel monoclonal antibody specifically binding to L-Thyroxine (T4) and compositions and kits comprising such antibodies. Furthermore, provided are polynucleotides encoding such monoclonal antibodies, host cells expressing said antibodies, methods of producing such antibodies and diagnostic methods using such monoclonal antibodies. The monoclonal antibody of the invention comprises a heavy chain variable domain (VH) comprising V or A in position 33; Y in position 50; W in position 52; I in position 98, G, A or V in position 99; Y in position 100; and I in position 100b; and a light chain variable domain (VL) comprising amino acids H or Y in position 28; N or K in position 29; W in position 32; G or A in position 91; Y, W or F in position 92; S or T in position 93; Y or F in position 95b; N, S, T or Q in position 95c; and H in position 96, wherein the positions of the amino acids in the VH and the VL are indicated according to the Kabat numbering scheme, respectively.
An optical system configured for Fourier Ptychography is disclosed, comprising at least one array of light emitters, wherein each light emitter is configured for emitting at least one illumination light beam towards a sample plane; at least one lenslet array comprising a plurality of lenses, wherein each of the lenses is dedicated to at least one of the light emitters of the array of light emitters, wherein orientation and shape of the respective lens is adapted to the dedicated light emitter, wherein the lenslet array is configured for focusing the illumination light beams in the sample plane. The array of light emitters and the lenslet array are arranged such that the sample plane is illuminated by the illumination light beams under different illumination angles.
A computer implemented method for automated quality check of chromatographic and/or mass spectral data is disclosed. The method comprises the following steps:
a) (110) providing processed chromatographic and/or mass spectral data obtained by at least one mass spectrometry device (112);
b) (114) classifying quality of the chromatographic and/or mass spectral data by applying at least one trained machine learning model on the chromatographic and/or mass spectral data, wherein the trained machine learning model uses at least one regression model (116), wherein the trained machine learning model is trained on at least one training dataset comprising historical and/or semi-synthetic chromatographic and/or mass spectral data, wherein the trained machine learning model is an analyte-specific trained machine learning model.
An analytical system comprising a mass spectrometer and an ionization source. The analytical system further comprises an analytical fluidic system connectable to the ionization source for infusing samples into the mass spectrometer via the ionization source, a downstream pump fluidically connectable to the ionization source via the downstream valve, where the downstream pump is fluidically connected to a plurality of fluid containers comprising respective fluids, the fluids comprising a concentrated composition for calibrating the mass spectrometer and at least one diluent for diluting the at least one concentrated composition. The analytical system further comprises a controller configured to control the downstream pump to obtain at least one diluted composition by automatically mixing a concentrated composition with a diluent with a predetermined dilution factor, to infuse the diluted composition into the ionization source, to obtain a mass spectrum of the diluted composition and to execute a calibration of the mass spectrometer. A respective automated analytical method.
The present invention relates to a method for determining an analyte in a mass spectrometry (MS) device comprising a first and a second mass filter, said method comprising (i) filtering for an analyte ion species in the first mass filter; (ii) optionally fragmenting at least a fraction of ions obtained by the filtering in step (i) in a collision cell, wherein the collision energy of said fragmenting is selected to be lower than a predetermined collision energy causing fragmentation of said analyte ion species; (iii) filtering for said analyte ion species filtered for in step (i) in the second mass filter, and (iv) detecting said analyte ion species filtered for in step (iii), thereby determining said analyte. Moreover, the present invention relates to devices, systems, and uses related to said method.
The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as disclosed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase.
A computer-implemented method for optimising an assignment of one or more medical samples to one or more analytical tests to be conducted on those medical samples. The method comprises the steps of: obtaining an initial assignment of the one or more medical samples to the one or more analytical tests; determining a compliance status for the or each medical sample, the compliance status indicating: (i) whether a sample quality metric of the or each medical sample violates an analytical test specification of the medical sample's assigned analytical test(s) in the initial assignment and/or (ii) whether the or each medical sample is unprocessable; and performing a mitigation action if one or more compliance status indicate: (i) that the sample quality metric of a given medical sample violates the analytical test specification and/or (ii) a given medical sample is unprocessable.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
41.
TRANSPORT DEVICE AND LABORATORY SAMPLE DISTRIBUTION SYSTEM
The invention relates to a transport device for a laboratory sample distribution system, the transport device comprising a top cover having a transport surface, the transport surface being adapted to carry sample container carriers, an electromagnetic actuation assembly, the electromagnetic actuation assembly being adapted to generate a magnetic field at the transport surface for magnetic drive-interaction with a sample container carrier placed thereon, a support structure for carrying the actuation assembly, a sensor board being arranged in between the support structure and the top cover, the sensor board being adapted to detect a position of a sample container carrier placed on the transport surface with respect to the transport device, and elastic elements which are biased in between the sensor board and the support structure so that the sensor board is held flush against an inside surface of the top cover by a biasing force resulting from the biasing of the elastic elements.
The present invention relates to a method for labeling an analyte in a sample, said method comprising (a) providing a detection agent binding to the analyte and conjugating said detection agent with an indicator agent to produce a conjugation product; (b) contacting said sample with said conjugation product of step (a); wherein said step (b) is performed directly after completion of step (a) and wherein steps (a) and (b) are performed by the same labeling device; and to labeling devices, systems, and uses related thereto.
The invention relates to an adjustable adapter for closing a c-shaped gap in between two modules of a laboratory system, the adjustable adapter comprising a base extending along a width direction (W) of the adjustable adapter, and a pair of legs each protruding from the base in a length direction (L) of the adjustable adapter so that the base and the legs are arranged in a c-shape of the adjustable adapter, the base being adjustable to set its dimension (D, D1, D2) along the length direction (L).
The present invention relates to a monoclonal antibody or an antigen-binding fragment thereof specifically binding to Aβ42 with advantageous features for Aβ42 detection in vitro using immunoassays. Also provided is a polynucleotide or a set of polynucleotides encoding the same and a vector comprising said polynucleotide(s). Further provided is a host cell comprising the polynucleotide(s) and a corresponding production process using this host cell. Also provided herein are uses and methods employing the monoclonal antibody or an antigen-binding fragment thereof specifically binding to Aβ42 as provided herein.
There is provided an automatic analyzer equipped with a disk-type container placement mechanism, which enables an operator to perform additional placement of a container during analysis operation. The automatic analyzer includes a storage unit previously stored with a sample container 103 holding a sample before measurement of the sample, a dispensing mechanism 4 that sucks the sample from the sample container, an input unit that receives a command to store an emergency sample in the storage unit, the control unit 7 that controls such that, after a first operation being performed by the dispensing mechanism at a point of time when the command is received is completed, a second operation scheduled to be performed next by the dispensing mechanism is not started, and a display unit that prompts a user to store the emergency sample in the storage unit, in which the storage unit includes a first storage unit that stores an ordinary sample and a second storage unit that stores the emergency sample, and after controlling such that the second operation is not started, the control unit controls the second storage unit to move to a position where the emergency sample is inserted by a user.
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
G01N 35/10 - Devices for transferring samples to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
A system for securely storing data, such as sensitive personal data, including an interface configured with a REST API, an authentication module, at least one target database for storing the data, and a data access module which is configured to receive requests from a client computer by means of the interface, query data from the at least one target database in response to the received request, determine whether the client computer and/or the user has permission to query, and generate a response data set to respond to the request and transmit it to the client computer, wherein at least some data of the response data set is anonymised if restricted authentication is determined.
A method of determining the concentration of an analyte comprising: providing a sensor device comprising:
a field effect transistor having a source electrode, a drain electrode and a gate electrode,
a sensing electrode electrically connected or integrated into the gate electrode, and
a control device for applying operation parameters to the field effect transistor and for monitoring a signal value with the field effect transistor;
selecting a set of operation parameters of the field effect transistor, the selecting comprising performing evaluation measurements with the field effect transistor using various sets of operation parameter candidates and selecting a set in accordance with optimization criterion monitored during the evaluation measurements; and
detecting the concentration by applying the selected set of operation parameters to the field effect transistor and determining a signal value with the field effect transistor.
A method of determining the concentration of an analyte comprising: providing a sensor device comprising:
a field effect transistor having a source electrode, a drain electrode and a gate electrode,
a sensing electrode electrically connected or integrated into the gate electrode, and
a control device for applying operation parameters to the field effect transistor and for monitoring a signal value with the field effect transistor;
selecting a set of operation parameters of the field effect transistor, the selecting comprising performing evaluation measurements with the field effect transistor using various sets of operation parameter candidates and selecting a set in accordance with optimization criterion monitored during the evaluation measurements; and
detecting the concentration by applying the selected set of operation parameters to the field effect transistor and determining a signal value with the field effect transistor.
Further, a sensor device for determining the concentration of an analyte in a sample.
The invention relates to a chute arrangement for a cap-removal apparatus, the cap removal apparatus being configured to remove caps from sample containers, the chute arrangement comprising a chute for transporting removed caps through a transport space of the chute arrangement, a sensor for detecting caps passing through a detection range of the sensor, the transport space being partially delimited by a chute bottom of the chute, the chute bottom being inclined with respect to gravity, the detection range protruding into the transport space, the detection range having a range border within the transport space, and the range border facing the chute bottom at a distance so that a bypass portion of the transport space is formed in between the chute bottom and the detection range.
A laboratory apparatus comprising a housing, wherein the housing comprises a through-opening, wherein the through-opening is adapted for passing through it a transport device for transporting laboratory sample containers in and/or out of the housing, and a cover, wherein the cover comprises at least two ring segments, wherein the ring segments are adjustable to each other between a distant adjustment with at least one distance in between ends of the ring segments for arranging them around the passed through transport device and a near adjustment with less or no distance in between the ends of the ring segments for surrounding the passed through transport device, and wherein the cover in the near adjustment is adapted to cover a part of the through-opening left free by the passed through transport device, wherein the laboratory apparatus is a pre-analytical, analytical, and/or post-analytical laboratory apparatus, in particular a sorting module.
The present invention relates to a modified antibody comprising a heavy chain and a light chain, wherein the antibody is modified to include in one or more of its immunoglobulin polypeptide chains one or more first recognition site(s) for the transglutaminase from Kutzneria albida (KalbTG) or a functionally active variant thereof. The one or more first recognition site(s) are introduced at one or more selected position(s) within an antibody's heavy chain and/or an antibody's light chain. The invention further relates to one or more nucleic acid(s) encoding an immunoglobulin polypeptide chain including the one or more recognition site(s), a site-specifically conjugated antibody comprising the modified antibody and one or more labelling domain(s) covalently attached to one or more first recognition sites, a kit for producing the conjugated antibody, a method of specifically labelling the modified antibody by way of site-specific conjugation, the use of the modified antibody for producing a specifically site-specifically conjugated antibody, a method of detecting a target in a sample and the use of the site-specifically conjugated antibody in the detection of a target and/or in the diagnosis.
The present invention relates to an in vitro method for cultivating one or more antibody expressing cell(s). The method comprises cultivating one or more antibody expressing cell(s) obtained from peripheral blood in the presence of IL-2, IL-21 and a non-cell surface presented CD40-stimulating agent and in the absence of feeder cells. Moreover, herein provided are methods for producing antibodies comprising the step of cultivating one or more antibody expressing cell(s) according to the method of the invention, a novel CD40-stimulating agent and uses therefrom as well as a cell culture medium.
A light source (112) for generating illumination light for illuminating at least one sample is disclosed. The light source (112) comprises
at least one array of light emitters (114), wherein each of the light emitters (114) is configured for emitting at least one light beam along a light beam path, wherein the light beam has a predefined wavelength range, and
at least one reflective optical grating (116) configured for overlaying the light beam paths, at least one transfer element (118);
wherein the transfer element (118) is arranged between the array of light emitters (114) and the optical grating (116) such that the transfer element (118) directs the emitted light beams onto the optical grating (116) and provides the light beams reflected from the optical grating (116) and impinging on the transfer element (118) into at least one measurement channel (120), wherein the measurement channel (120) is configured for receiving at least one sample.
G01N 21/359 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light
G01N 21/33 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
G01N 21/3577 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing liquids, e.g. polluted water
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Medical diagnostic reagents, namely, chemical, biochemical and biological-based medical diagnostic reagents; diagnostic reagents for clinical medical purposes; medical diagnostic reagents for clinical medical purposes; diagnostic reagents for medical use in in-vitro diagnosis used by medical laboratories Medical apparatus, namely, clinical chemistry analyzers for use in the analysis of biological samples for the presence, absence, or quantity of medically significant analytes for clinical medical diagnostic purposes
54.
TRANSFER DEVICE FOR TRANSFERRING SAMPLE CONTAINERS IN A SAMPLE HANDLING SYSTEM
A transfer device (110) for transferring sample containers in a sample handling system (112) is disclosed. The transfer device (110) comprises:
at least one transport device (114) comprising an array (116) of electromagnetic actuators (118), specifically electromagnetic actuators (118) comprising electromagnetic coils (120);
at least one moving unit (122) comprising at least one permanent magnet (124), wherein the moving unit (122) is movable in at least one movement plane (126), specifically in at least one movement plane (126) of the moving unit (122) defined by at least two moving directions (128), through the array (116) by magnetic interaction of the permanent magnet (124) with the electromagnetic actuators (118); and
at least one gripper unit (130) for positioning at least one of the sample containers, wherein the gripper unit (130) is movable in at least one gripping direction (132) essentially perpendicular to the movement plane (126), wherein the gripping unit (130) is attached to the moving unit (122).
A transfer device (110) for transferring sample containers in a sample handling system (112) is disclosed. The transfer device (110) comprises:
at least one transport device (114) comprising an array (116) of electromagnetic actuators (118), specifically electromagnetic actuators (118) comprising electromagnetic coils (120);
at least one moving unit (122) comprising at least one permanent magnet (124), wherein the moving unit (122) is movable in at least one movement plane (126), specifically in at least one movement plane (126) of the moving unit (122) defined by at least two moving directions (128), through the array (116) by magnetic interaction of the permanent magnet (124) with the electromagnetic actuators (118); and
at least one gripper unit (130) for positioning at least one of the sample containers, wherein the gripper unit (130) is movable in at least one gripping direction (132) essentially perpendicular to the movement plane (126), wherein the gripping unit (130) is attached to the moving unit (122).
Further disclosed is a sample handling system (112) for handling a plurality of sample containers and a method for transferring sample containers in a sample handling system (112).
The present invention relates to a method for determining an analyte of interest by frequency detection and the use thereof, a modified nanopore, an analyzing system, a kit and the uses thereof.
A computer-implemented method generates a message filter configuration based on a message priority indication of analytical device status messages received from a first analyzer network, the configuration based on identifying a type of analytical device status data associated with the message priority indication. The method includes communicating the message filter configuration, or a portion thereof, to a second analyzer network comprising a second analytical device.
H04L 47/24 - Traffic characterised by specific attributes, e.g. priority or QoS
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
H04L 43/062 - Generation of reports related to network traffic
57.
METHOD AND SYSTEM FOR OPERATING A LABORATORY AUTOMATION SYSTEM
A method for operating a laboratory automation system, the laboratory automation system comprising a carrier comprising a reception place for receiving a sample container configured to contain a sample to be analyzed by a laboratory device; a placement device configured to pick and place the sample container; an imaging device; and a data processing device comprising at least one processor and a memory. The method comprises detecting an image of the reception place; determining whether the reception place is free for receiving the sample container and the reception place is configured to receive the sample container, by applying a machine learning algorithm for image analysis of the image of the reception place; and placing the sample container in the reception place by the placement device if the reception place is determined as free and configured to receive the sample container. Further, a laboratory automation system is disclosed.
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
Classification of cell types A computer-implemented method of classifying cell types comprises: receiving image data representing a digital test image, the digital test image depicting a cell; applying a classifier model to the received image data, the classifier model configured to output a cell type of the cell depicted in the digital test image, wherein: the classifier model has been trained using training data comprising a plurality of digital records, each digital record comprising: training image data representing a digital training image depicting a cell; and a label indicative of the cell type of the cell depicted in the digital training image; and determining one or more digital reference images which depict cells most similar to the cell depicted in the digital test image; generating instructions which, when executed by a display component of a computing device, cause the display component to display: the cell type output by the classifier model; and the determined one or more digital reference images which depict cells most similar to the cell depicted in the digital test image. A corresponding diagnostic support and similar computer-implemented methods are also provided.
G06V 10/44 - Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersectionsConnectivity analysis, e.g. of connected components
G06V 10/74 - Image or video pattern matchingProximity measures in feature spaces
G06V 10/762 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using clustering, e.g. of similar faces in social networks
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G06V 10/778 - Active pattern-learning, e.g. online learning of image or video features
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
G06V 10/94 - Hardware or software architectures specially adapted for image or video understanding
G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
G06F 18/21 - Design or setup of recognition systems or techniquesExtraction of features in feature spaceBlind source separation
G06F 18/40 - Software arrangements specially adapted for pattern recognition, e.g. user interfaces or toolboxes therefor
A computer implemented method of a design enterprise network for facilitating remote configuration of a software instance comprised in a laboratory enterprise network, wherein the laboratory enterprise network is communicably coupled to an in vitro diagnostics (IVD) network, wherein the IVD network comprises at least one IVD instrument, and wherein the computer implemented method comprises obtaining by a generator computing instance comprised in a design enterprise network, a configuration definition input for configuring the software instance and generating, by the generator computing instance comprised in the design enterprise network, a configuration object based on the configuration definition input.
G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
60.
HYDROPHILIC AZADIBENZOCYCLOOCTYNE DERIVATIVES AND METAL-FREE CLICK REACTIONS WITH THESE HYDROPHILIC AZADIBENZOCYCLOOCTYNE DERIVATIVES
The invention relates in a first aspect to an azadibenzocyclooctyne derivative according to formula (I) or a salt thereof having specific substituents at the benzo rings of the DIBAC structure and having specific substituents connected to the nitrogen atom of the DIBAC structure. A second aspect of the invention is directed to a conjugate of formula (II), wherein a substituent R6 is connected to the N atom of the 8 membered ring of the DIBAC structure via a linker structure —C(═O)-[L]n-Z—. A third aspect of the invention relates to a method for the modification of a target molecule, wherein a conjugate according to the second aspect is reacted with a target molecule comprising a 1,3-dipole group or a 1,3-(hetero)diene group. In a fourth aspect, the invention is directed to the use of the conjugate according to the second aspect for bioorthogonal labeling and/or modification of a target molecule. A fifth aspect of the invention relates to a modified target molecule comprising the reaction product of a conjugate according to the second aspect and a target molecule comprising a 1,3-dipole group or a 1,3-(hetero)diene group, obtained or obtainable from the method of the third aspect. In a sixth aspect, the invention is related to a kit comprising a modified target molecule according to the fifth aspect as detector reagent and a suitable capture reagent.
C07D 225/08 - Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with two six-membered rings
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A computer-implemented method for processing electronic healthcare data, comprising: receiving, at an intermediate data processing device, a data packet from a data source, said data packet being for transmission to a data consumer across a network and including electronic healthcare data, said intermediate data processing device being connected between the data source and the data consumer in the network; performing, by the intermediate data processing device, a validation process of the data packet by comparison of the data packet to a healthcare data packet scheme; acknowledging, to the data source, receipt of a valid data packet at the intermediate data processing device from the data source when the data packet has been validated by the validation process; and transmitting the data packet on to the data consumer when the data packet has been validated by the validation process.
The invention relates to a laboratory sample container carrier handling apparatus comprising a revolving device and a guiding surface, wherein an entry segment of the guiding surface is adapted to smoothly receive a laboratory sample container carrier. The invention further relates to a laboratory automation system comprising such a laboratory sample container carrier handling apparatus and to a use of such a laboratory sample container carrier handling apparatus for handling a laboratory sample container carrier in, in particular such, a laboratory automation system.
The present invention relates to a method for assessing chronic liver disease in a subject, said method comprising (a) determining an amount of the biomarker Insulin-like growth factor-binding protein 3 (IGFBP3) in a sample from said subject; (b) determining an amount of the biomarker gamma-glutamyltransferase (GGT) in said sample; (c) comparing the amounts of the biomarkers determined in steps (a) and (b) to references for said biomarkers and/or calculating a score for assessing chronic liver disease; and (d) assessing chronic liver disease in said subject based on the comparison and/or the calculation made in step (c). The present invention further relates to computer-implemented methods, databases, devices, and uses related thereto.
C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
64.
Diagnostic System, Automatic Analyzer, and Diagnostic Method
To improve diagnostic accuracy of a sensor of an automatic analyzer. A diagnostic system for diagnosing a sensor that is provided in an automatic analyzer and outputs an analog electrical signal includes a memory that stores data of the electrical signal output by the sensor and a replacement history of the sensor, and a processing device that processes data recorded in the memory, in which the processing device reads, from the memory, data for a set reference period from among electrical signal data output by a past sensor that was used in the automatic analyzer, calculates a statistical value of the data for a reference period, reads, from the memory, data recorded during a set evaluation period from among electrical signal data output by a sensor for diagnosis that is being used in the automatic analyzer, calculates a statistical value of the data for an evaluation period, and determines an abnormality of the sensor for diagnosis based on a difference obtained from the statistical value of the reference period and the statistical value of the evaluation period.
An in vitro method is disclosed for detecting an antibody to p53 (anti-p53 antibody) in a sample, the method comprising: incubating a sample to be analyzed with a p53 capture antigen and a p53 detection antigen, whereby a complex comprising the p53 capture antigen, the anti-p53 antibody and the p53 detection antigen is formed, separating the complex formed from unbound detection antigen and measuring the complex obtained via the detection antigen comprised therein, thereby detecting the anti-p53 antibody comprised in the sample.
The present invention relates to methods of assessing whether a patient has adenomyosis or is at risk of developing adenomyosis, to methods of selecting a patient for therapy of adenomyosis, and methods of monitoring a patient suffering from adenomyosis or being treated for adenomyosis, by determining the amount or concentration of sFRP4 in a sample of the patient, and comparing the determined amount or concentration to a reference.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G01N 33/536 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
A time tracking device (112) for monitoring system performance of at least one laboratory instrument is proposed. The time tracking device (112) comprises at least one support structure (114). The time tracking device (112) further comprises at least one electronics unit (116) and at least one motion sensor (118) housed by the support structure (114). The motion sensor (118) is configured for detecting a change of motion and/or orientation of the time tracking device (112). The electronics unit (116) is configured for measuring time, wherein a time measurement is initiated by detecting a change of motion and/or orientation of the time tracking device (112) and is terminated by detecting a subsequent change of motion and/or orientation of the time tracking device (112). The support structure (114) is a polygonal support structure (114) comprising a plurality of faces (120), wherein the support structure (114) comprises at least two interactive faces (136). Each of the interactive faces (136) comprises at least one user interface (138) comprising at least one display device (140). Each of the interactive faces (136) is configured for displaying at least one status indication (171) of the laboratory instrument, wherein the interactive face (136) matching a current status of the laboratory instrument is selectable by a user via changing motion and/or orientation of the time tracking device (112). The time tracking device (112) is con-figured for providing data relating to the measured time via at least one communication interface (172).
G04F 1/00 - Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers
68.
APPARATUS FOR MEASURING A FILLING LEVEL OF A SAMPLE CONTAINER
The invention relates to an apparatus (1) for measuring a filling level of a sample container via laser transmission detection, the apparatus (1) comprising a laser source arrangement (2) for emitting light (L) of two distinctive wavelengths (A, B), a fiber optic (3) for guiding the light (L) emitted by the laser source arrangement (2), the fiber optic (3) extending from a first fiber portion (3) to a second fiber portion (5), the latter of which having a fiber ending (6) directed onto a target position (T) of the apparatus (1), such that a beam path (P) for light (L) leaving the fiber ending (6) is spanned toward the target position (T), a sample holder (7) for holding the sample container within the beam path (P), and a light transmission detector (D) for detecting light (L) reaching the target position (T) along the beam path (P), the light (L) reaching the target position (T) being transmitted by the sample container and/or a content thereof when placed within the beam path (P).
The present invention relates to a method of detecting the effect induced by a sodium-glucose cotransporter inhibitor (SGLTi ) in a subject suffering from a cardiovascular disease, the method comprising a) determining the amount of Fatty Acid Binding Protein 3 (FABP3) in a sample of the subject treated with SGLTi; and b) comparing the amount of said FABP3 to a reference amountAlso encompassed are computer-implemented methods, computer program products, devices and kits for carrying out the method of the present invention. The present invention further relates to the use of FABP3, the use of FABP3 and a cardiac injury marker, and/or the use of a detection agent of FABP3 or FABP3 and a cardiac injury marker for detecting the effect induced by a sodium-glucose cotransporter inhibitor (SGLTi) in a subject suffering from a cardiovascular disease.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Chemical, biological and biochemical preparations for the analysis of biological samples for medical purposes; medical diagnostic assays and reagents for the analysis of biological samples for clinical or medical purposes; diagnostic reagents and preparations for medical purposes; in vitro diagnostic agents for the analysis of biological samples for medical purposes Analyzers for the analysis of biological samples for medical diagnostic purposes
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Chemical, biological and biochemical preparations for the analysis of biological samples for medical purposes; medical diagnostic assays and reagents for the analysis of biological samples for clinical or medical purposes; diagnostic reagents and preparations for medical purposes; in vitro diagnostic agents for the analysis of biological samples for medical purposes Laboratory instruments for use in research and science, namely, analyzers for the analysis of biological samples for scientific or medical research use Analyzers for the analysis of biological samples for medical diagnostic purposes
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Chemical, biological and biochemical preparations for the analysis of biological samples for medical purposes; medical diagnostic assays and reagents for the analysis of biological samples for clinical or medical purposes; diagnostic reagents and preparations for medical purposes; in vitro diagnostic agents for the analysis of biological samples for medical purposes Analyzers for the analysis of biological samples for medical diagnostic purposes
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Chemical, biological and biochemical preparations for the analysis of biological samples for medical purposes; medical diagnostic assays and reagents for the analysis of biological samples for clinical or medical purposes; diagnostic reagents and preparations for medical purposes; in vitro diagnostic agents for the analysis of biological samples for medical purposes Laboratory instruments for use in research and science, namely, analyzers for the analysis of biological samples for scientific or medical research use Analyzers for the analysis of biological samples for medical diagnostic purposes
An analyzer system (110) is disclosed. The analyzer system (110) comprises:
at least one mass spectrometry device (112) having at least one electrospray ion source nozzle (114);
at least one liquid supply (116), wherein the liquid supply (116) is configured for providing at least one liquid having at least one analyte;
at least one gas supply (118), wherein the gas supply (118) is configured for providing at least one gas; and
at least one dopand gas supply (120), wherein the dopand gas supply (120) is configured for providing at least one chemical dopand gas having at least one chemical dopand (122) to the analyte provided by the liquid supply (116);
wherein the liquid supply (116) and the gas supply (118) are coupled to the mass spectrometry device (112) via the electrospray ion source nozzle (114), wherein the dopand gas supply (120) is connected to the gas supply (118).
A method for operating a laboratory automation system, comprising, a transport system, a plurality of transfer devices; a portable device; and a plurality of data communication modules. The method comprises: receiving device information for the devices in the portable device, the device information being indicative a device identification; receiving a first user input in the portable device, the user input being indicative of a selection of a first device from the plurality of devices; in response to receiving the first user input, pairing the first device with the transport system for data communication in operation of the first device for at least one of sample pre-analytics and sample analysis; and providing first pairing information in the portable device, the first paring information being indicative of the first device and the distribution system being paired successfully. Further, a laboratory automation system and a laboratory in-vitro diagnostics system are provided.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
A computer-implemented method of automatic registration of a device in a laboratory system comprising:
transmitting from the to be registered device specific information to a managing unit (“unit”) via a first interface;
the unit requesting a solution specific configuration from a remote infrastructure via a second interface, receiving the solution specific configuration from the remote infrastructure via the second interface, and transmitting the solution specific configuration to the device to be registered via the first interface, the solution specific configuration being based on the device specific information and configuration information about the laboratory system; and
transmitting a request from the unit comprising updated solution specific configuration to the laboratory devices, the updated solution specific configuration comprising information about the device to be registered and changes due to addition of said device, wherein the laboratory configuration step comprising providing the updated solution specific configuration to the remote infrastructure.
G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Laboratory instruments, namely, clinical chemistry analyzers and immunochemistry analyzers for the analysis of biological samples for the presence, absence, or quantity of medically significant analytes for scientific or medical research purposes; computer hardware and downloadable software for use with laboratory instruments, namely, for use in data analysis and database management Medical apparatus, namely, clinical chemistry analyzers and immunochemistry analyzers for use in the analysis of biological samples for the presence, absence, or quantity of medically significant analytes for clinical medical diagnostic purposes
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Laboratory instruments, namely, clinical chemistry analyzers and immunochemistry analyzers for the analysis of biological samples for the presence, absence, or quantity of medically significant analytes for scientific or medical research purposes; computer hardware and downloadable software for use with laboratory instruments, namely, for use in data analysis and database management Medical apparatus, namely, clinical chemistry analyzers and immunochemistry analyzers for use in the analysis of biological samples for the presence, absence, or quantity of medically significant analytes for clinical medical diagnostic purposes
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Laboratory instrument for the analysis of biological samples for the presence, absence, or quantity of medically significant analytes for use in the research and science industry; computer hardware and downloadable software for use with laboratory instruments, namely, for use in providing automation of laboratory processes, control and monitoring of laboratory instruments, connectivity, data analysis, and data management Medical diagnostic apparatus for the analysis of biological samples for the presence, absence, or quantity of medically significant analytes for medical diagnostic purposes
80.
STREM1 MARKER PANELS FOR EARLY DETECTION OF SEPSIS
The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being STREM1, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: Aspartate aminotransferase, Bilirubin, ESM-1, HBP (Heparin-binding protein), a cardiac Troponin, Alanine aminotransferase, and IL6, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being STREM1 and a second biomarker selected from the group consisting of: Aspartate aminotransferase, Bilirubin, ESM-1, HBP (Heparin-binding protein), a cardiac Troponin, Alanine aminotransferase, and IL6 or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
The present invention relates to diagnostic test and technology. In particular, the present invention relates to a method for determining an analyte suspected to be present in a sample comprising contacting said sample with a sensor element comprising i) an anchor layer which is present on a solid support, ii) a first binding agent which is capable of specifically binding to the analyte, which is anchored in the anchor layer and which comprises at least one detectable label, and iii) a second binding agent which is capable of specifically binding to the analyte when bound to the first binding agent and which is immobilized on the solid support, for a time and under conditions which allow for specific binding of the analyte suspected to be present in the sample to the first binding agent and specific binding of the second binding agent to the analyte bound to the first binding agent and detecting the formation of the complex of first binding agent, analyte and second binding agent whereby the analyte is determined. Moreover, provided is a device for determining an analyte suspected to be present in a sample and the use thereof for determining an analyte suspected to be present in a sample in said sample. Moreover, the present invention contemplates a kit for determining an analyte suspected to be present in a sample.
G01N 33/544 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
The present invention relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being GDF-15, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: sFLT1, Cystatin C, IGFBP-7, Bilirubin, ESM-1, sTREM-1, Procalcitonin, cardiac Troponin, BNP-type peptide, Alanine aminotransferase, and Aspartate aminotransferase, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being GDF-15 and a second biomarker selected from the group consisting of sFLT1, Cystatin C, IGFBP-7, Bilirubin, ESM-1, sTREM-1, Procalcitonin, cardiac Troponin, BNP-type peptide, Alanine aminotransferase, and Aspartate aminotransferase or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being sFlt1, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: Cystatin C, IGFBP7, a cardiac Troponin, Creatinine, STREM1, PCT and Bilirubin, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being sFltl and a second biomarker selected from the group consisting of: Cystatin C, IGFBP7, a cardiac Troponin, Creatinine, sTREM1, PCT and Bilirubin, or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase
C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
C12Q 1/52 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase involving transaminase
G01N 33/70 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving creatine or creatinine
G01N 33/72 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood pigments, e.g. hemoglobin, bilirubin
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being ESM-1, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is Creatinine or a Cystatin C, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being ESM-1 and a second biomarker being Creatinine or a Cystatin C or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase
C12Q 1/52 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase involving transaminase
G01N 33/72 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood pigments, e.g. hemoglobin, bilirubin
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Paenibacillus polymyxa preproenzyme which is the precursor of a neutral protease, expression thereof in a transformed host organism, and methods for production of the neutral protease, by recombinant means. Further, use of the recombinantly produced neutral protease is disclosed in the field of cell biology, particularly for the purpose of tissue dissociation. The disclosure also includes blends with other proteases. Further disclosed are nucleotide sequences encoding the neutral protease.
A system for supplementing measurement results of automated analyzers is presented. The system includes a computer device configured for obtaining a result of a measurement performed by an automated analyzer, the computer device and the automated analyzer being located within a privileged computer network, obtaining a context related algorithm associated with the result of the measurement defining one or more triggering conditions and context related information from a computer device residing outside of the privileged computer network at the computer device and processing the result of the measurement by using the context related algorithm to generate a context specific supplement to the result of the measurement at the computer device.
G06F 17/18 - Complex mathematical operations for evaluating statistical data
G06F 21/62 - Protecting access to data via a platform, e.g. using keys or access control rules
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being PCT, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: a cardiac Troponin, Creatinine, a BNP-type peptide, sTREM1, ESM-1, Haptoglobin, Heparin binding protein (HBP) and Aspartate aminotransferase, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being PCT and a second biomarker selected from the group consisting of: a cardiac Troponin, Creatinine, a BNP-type peptide, sTREM1, ESM-1, Haptoglobin, Heparin binding protein (HBP) and Aspartate aminotransferase, or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G01N 33/70 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving creatine or creatinine
G01N 33/72 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood pigments, e.g. hemoglobin, bilirubin
G01N 33/74 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving hormones
88.
IGFBP7 MARKER PANELS FOR EARLY DETECTION OF SEPSIS
The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being IGFBP7, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: PCT, IL6, a cardiac Troponin, Albumin, CRP, Bilirubin, Ferritin, ESM-1, Aspartate aminotransferase, a BNP-type peptide, Alanine aminotransferase, Creatinine, and suPAR, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being IGFBP7 and a second biomarker selected from the group consisting of: PCT, IL6, a cardiac Troponin, Albumin, CRP, Bilirubin, Ferritin, ESM-1, Aspartate aminotransferase, a BNP-type peptide, Alanine aminotransferase, Creatinine, and suPAR, or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
89.
METHOD FOR DETERMINING AT LEAST ONE ANALYTE OF INTEREST
The present invention relates to a method for determining at least one analyte of interest. The present invention further relates to a sample element, an inlet, a composition, a kit and the use thereof for determining at least one analyte of interest.
An information processing device includes a first determination unit that inputs information related to total protein (TP), cholinesterase (ChE), total cholesterol (TC), creatinine (CREA), and creatine phosphokinase (CPK) to a first learning-completed model based on information related to a blood examination of a subject and outputs information related to whether thyroid stimulation hormone (TSH) of the subject is in a range for which medical treatment is needed.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G01N 33/70 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving creatine or creatinine
G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being IL-6, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is Creatinine or a cardiac Troponin, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being IL-6 and a second biomarker being a cardiac Troponin or Creatinine or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
This automated analysis device comprises a first analyzing unit for performing analysis related to a first analysis item group, a second analyzing unit for performing analysis of a second analysis item group using a measuring principle different from the first analyzing unit, a reagent storage unit for storing at least one first reagent vessel accommodating a reagent used for the analysis by the first analyzing unit and at least one second reagent vessel for accommodating a reagent used for the analysis by the second analyzing unit, an agitating unit for agitating a solution in the second reagent vessel, and a control unit for controlling operation of the agitating unit, wherein the control unit controls the operation of the agitating unit to agitate a solution in the first reagent vessel. This makes it possible to agitate a plurality of reagents used for a plurality of measurements that employ different principles, while suppressing an increase in the size of the device.
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
A first aspect of the invention is related to the use of a (poly)label for generating a quantifiable signal for an analyte of interest in mass spectrometry, wherein the (poly)label has the structure (I). In a second aspect, the invention is directed to a process for modifying an analyte of interest for obtaining an increased intensity signal in mass spectrometry. A third aspect of the invention is directed to a method for determining an analyte of interest by mass spectrometry. A fourth aspect of the invention relates to a (poly)label having structure of formula (Ia). In a fifth aspect, the invention is related to a reaction product comprising a polypeptide and a (poly)label having the general structure (III).
The present invention relates to a solid phase peptide synthesis (SPPS) solvent system and use thereof. The present invention further relates to a solid phase peptide synthesis (SPPS), a kit, a peptide synthesizer and the use thereof.
The present invention relates to an instrument for automatically removing sealing covers from sample vessels (and/or for automatically sealing or resealing sample vessels with sealing covers, the instrument comprising a vessel holder for holding a sample vessel, and a suction/induction device comprising a suction member for holding a sealing cover, and an induction member comprising at least one induction coil, with the suction/induction device and the vessel holder being arranged in an axially movable manner with regard to each other, and, in use, the at least one induction coil is arranged above a bottom of the suction member. In addition, the present invention relates to a laboratory automation system comprising such instrument as well as a plurality of pre-analytical, analytical and/or post-analytical stations, and also relates to a method of automatically removing sealing covers from sample vessels and a method of automatically sealing or resealing sample vessels with sealing covers.
An automated method of washing a fluidic system 210 of an IVD analyzer 200 from a previous fluid is disclosed, the fluidic system 210 comprising at least one fluidic path 211, 213, 215. The method comprises controlling by a controller 250 a pump 240 and at least one fluid-selection valve 230 for pumping a wash fluid 221 and/or air 232 through the at least one fluidic path, wherein in a time-priority mode 10 the method comprises pumping at higher speed air, in a first step 11, in order to remove the previous fluid from the at least one fluidic path, and wash-fluid plugs alternated to air plugs, in a second step 12, in order to wash out residuals of the previous fluid, and wherein in a wash-fluid-priority mode 20 the controller 250 is configured to operate according to either a sample-wash mode 30 if the previous fluid is a sample 2 or according to an other-fluid-wash mode 40 if the previous fluid is any fluid other than a sample 2, wherein in the sample-wash mode 30 the method comprises pumping air at lower speed, in a first step 31, in order to remove the previous fluid from the at least one fluidic path, pumping at least one wash-fluid plug at higher speed, in a second step 32, and pumping wash-fluid plugs alternated to air plugs at lower speed, in a third step 33, in order to wash out residuals of the previous fluid, and wherein in the other-fluid-wash mode 40 the method comprises pumping air at lower speed, in a first step 41, in order to remove the previous fluid from the at least one fluidic path and pumping wash-fluid plugs alternated to air plugs at lower speed, in a second step 42, in order to wash out residuals of the previous fluid.
A method for automated microscopic scanning is disclosed. The method comprises the following steps: a. (110) image data acquisition, wherein the image data acquisition comprises generating microscopic images of a sample by scanning at least one pre-defined scanning area of at least one microscopic slide (128)carrying the sample by using at least one image scanner (122); b. (112) determining at least one feature characterizing at least one biological entity of the sample by applying at least one classification algorithm to the microscopic images by using at least one processing device, wherein the feature is compared to at least one pre-defined criterion, wherein the determining and the comparing is performed in parallel to the image data acquisition, wherein the image data acquisition of said microscopic slide (128) is discontinued by at least one controlling device of the image scanner (122) as soon as the determined feature reaches the pre- defined criterion; and c. repeating the method for a next microscopic slide (128).
The present disclosure refers to a method for operating an in-vitro-diagnostics laboratory system, IVD laboratory system. The IVD laboratory system has a housing (12) with an opening (12a); an actuator device (10), arranged in the housing (12), for processing sample containers; a cover (11) configured to cover the opening (12a); a cooling device (14) configured to cool the sample containers; and a cooling device control unit (15) configured to control operation of the cooling device (14). The method comprises: determining whether the cover (11) is open; determining whether the cooling device control unit (15) is active; in a normal system mode, disabling operation of the actuator device (10) based on at least one of the cover (11) being open and the cooling device control unit (15) being inactive; and in a bypass system mode, enabling operation of the actuator device (10) based on the cover (11) being open and the cooling device control unit (15) being active.
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
The invention relates to a method of operating a gripping device (100) being adapted to insert sample containers (1) into sample container racks (2) and/or remove sample containers (1) from sample container racks (2), wherein the gripping device (100) comprises gripping fingers (3) being adapted to grip the sample containers (1), wherein the method comprises the steps: moving the gripping fingers (3) in z-direction to insert a sample container (1) into a sample container rack (2) or remove a sample container (1) from a sample container rack (2), determining, if the gripping fingers (3) get in contact with the sample container rack (2), and performing an error procedure, if the gripping fingers (3) get in contact with the sample container rack (2).
B25J 19/00 - Accessories fitted to manipulators, e.g. for monitoring, for viewingSafety devices combined with or specially adapted for use in connection with manipulators
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
100.
DETECTION OF AN ANALYTE OF INTEREST BY A CHIP BASED NANOESI DETECTION SYSTEM
The present invention relates to a method, a diagnostic system, a kit and the use thereof for efficiently detection of an analyte of interest by a chip based nanoESI detection system.
